The immune system is complex and traditional preclinical toxicity models often fail to predict the human immune response. Cyprotex has developed a panel of immune-specific in vitro toxicity assays using human cell-based models to understand the immunogenic and cytotoxic potential of various drug modalities such as small molecules, biologics and oligonucleotides. Both inter-individual and population wide responses can be assessed using our on-site biobank of HLA-types immunocompetant cells.
Read our fact sheet to learn more about our immunotoxicity services including the PBMC cytokine storm panel, the T-cell immunogenicity risk panel, the PBMC proliferation assay, the PBMC cytotoxicity assay and the dendritic cell activation assay. Cyprotex also offers a range of skin sensitization assays such as the DPRA assay, the KeratinoSensTM assay and the U-SENSTM assay.